Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialRalf Gold, Gilmore O’Neill, Xavier Montalbán et al.|The Lancet|2013Cited by 287
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trialGavin Giovannoni, Gilmore O’Neill, Ralf Gold et al.|The Lancet Neurology|2014Cited by 94